tbuckley/cabot-search huggingface dataset:
Attacking Host of Risk Factors Is Key to Treating, Preventing Diabetic Kidney Disease
Authors: Mike Mitka
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Personality disorder
Authors: L. Gask, M. Evans, D. Kessler
Journal: BMJ (2013)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Personality disorder Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Drug companies' leaflets dubbed “confusing”
Authors: Roger Dobson
Journal: BMJ (2000)

Drug companies are being urged to improve their product information leaflets for patients after a report from the Consumers Association warning that they can cause confusion and alarm.

Many of the leaflets were found to have so much information crammed into them that they were illegible, while some had too much technical and medical jargon. Others were found to contain vague and sometimes contradictory statements.

The reports said …
Quantitative cytomegalovirus DNA level in the blood and its relationship to cytomegalovirus retinitis in patients with acquired immune deficiency syndrome11Digene Hybrid Capture System assays were provided by Digene Corporation, Beltsville, Maryland. The authors have no proprietary interest in the development or marketing of Digene Hybrid Capture System or competing tests.
Authors: Adnan Tufail, Ardis A Moe, Marjorie J Miller, Elizabeth A Wagar, David A Bruckner, Gary N Holland
Journal: Ophthalmology (1999)
Abstract 2732: Identification of a small molecule selectively kill mismatch repair deficient tumors
Authors: Kyungjae Myung
Journal: Cancer Research (2014)

Abstract Lynch Syndrome, a genetic disorder caused by defects in the DNA mismatch repair (MMR) pathway, accounts for approximately 5% of all colon cancer cases. Lynch Syndrome tumors have proven to be resistant to most conventional chemotherapeutic agents, making surgery the best treatment option available. Here we screened NIH small molecule library for their ability to selectively kill cells with mutations in the MSH2 gene, and identified a small molecule that could target MMR-deficient cancer cells. This small molecule intercalates DNA, trigering a DNA damage response in MSH2-proficeint cells. In MSH2-deficient cells, continued replication in the presence of this small molecule leads to the formation of DNA double-strand breaks and ultimately results in apoptosis in the G2/M phase of the cell cycle. In addition, this small molecule is not mutagenic. Our results suggest that this small molecule may offer an improved treatment option for patients with tumors characterized mutations in the MMR pathway. Citation Format: Kyungjae Myung. Identification of a small molecule selectively kill mismatch repair deficient tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2732. doi:10.1158/1538-7445.AM2014-2732
Assessing Genetic Risks: Implications for Health and Social Policy
Authors: A. P Read
Journal: BMJ (1994)

Ed Lori B Andrews, Jane E Fullarton, Neil A Holtzman, Arno G Motulsky National Academy Press, £28.95, pp 338 ISBN 0-309-04798-6

Genetic screening tends to serve as a flypaper on which our hovering fears of a Brave New World alight and stick. In the future of all-conquering genetic technology, who should be screened for what and by whom? Here is a dense report, compiled by a committee of the great and the good, with hundreds of recommendations for action and inaction. How much …
Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B
Authors: Lucas Berk, Solko W. Schalm, Robert A. de Man, Rudolf A. Heytink, Pierre Berthelot, Christian Brechot, Bernard Boboc, Françoise Degos, Patrick Marcellin, Jean-Pierre Benhamou, Georg Hess, Siegbert Rossol, Karl-Hermann Meyer zum Büschenfelde, Robert A.F.M. Chamuleau, Peter L.M. Jansen, Henk W. Reesink, Beat Meyer, Christoph Beglinger, Georg A. Stalder, Jannie W. den Ouden-Muller, Maurits de Jong
Journal: Journal of Hepatology (1992)
Herbalist (The Healer)
Authors: M. Therese Southgate
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation Methods in Medical Informatics, by Charles P Friedman, Jeremy C Wyatt
Authors: J. Faughnan
Journal: BMJ (1997)

Charles P Friedman, Jeremy C Wyatt: Springer, £40, pp 311 ISBN 3 540 94228 9

Computers have not been kind to physicians. They enable monitoring and pestering everywhere. None the less, there have been generations of computer enthusiasts in health care, including many doctors. The appeal seems obvious: we forget easily, the computer never forgets; we are slow to do simple things, the computer is fast; we tire, the machine is tireless.

Even 30 years ago it seemed a natural partnership. With the computer to leverage our strengths and ease our frailties, we could all be Oslers. …
Avian Flu Concerns
Authors: Joan Stephenson
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reproducibility of patch tests
Authors: Jochen Brasch, Tilo Henseler, Werner Aberer, Gabriele Bäuerle, Peter J. Frosch, Thomas Fuchs, Veronika Fünfstück, Gabriele Kaiser, Gerd G. Lischka, Beate Pilz, Christine Sauer, Jörg Schaller, Brigitte Scheuer, Christiane Szliska
Journal: Journal of the American Academy of Dermatology (1994)
ANALGESIC EFFECT OF DEXTROPROPOXYPHENE HYDROCHLORIDE IN ELDERLY PATIENTS WITH CHRONIC PAIN SYNDROMES
Authors: R W BOYLE, C E SOLOMONSON, J R PETERSEN
Journal: Annals of Internal Medicine (1960)

Article1 January 1960ANALGESIC EFFECT OF DEXTROPROPOXYPHENE HYDROCHLORIDE IN ELDERLY PATIENTS WITH CHRONIC PAIN SYNDROMESR. W. BOYLE, M.D., F.A.C.P., C. E. SOLOMONSON, M.D., J. R. PETERSEN, M.D.R. W. BOYLE, M.D., F.A.C.P.Search for more papers by this author, C. E. SOLOMONSON, M.D.Search for more papers by this author, J. R. PETERSEN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-1-195 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPain is the symptom for which people most often seek medical attention. The relief of pain resulting from nonprogressive chronic illness has been difficult, since the agents most effective in the relief of such pain have in common the most undesirable side-effect, that of addiction. The search for an effective, non-narcotic analgesic has been stimulated by a need for an agent efficacious in the relief of chronic pain, yet free from the disadvantages of the opiates and their derivatives.Recently a new analgesic agent, dextropropoxyphene hydrochloride (Darvon),‡has been introduced for use by the medical profession. Clinical trials have indicated...Bibliography1. Bross IJ: Ridit analysis, Biometrics 14: 18 (Mar.) 1958. CrossrefGoogle Scholar2. Beecher HK: Limiting factors in experimental pain, J. Chron. Dis. 4: 11, 1956. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Milwaukee, Wisconsin*Received for publication May 18, 1959.From the Department of Physical Medicine and Rehabilitation and the Department of Medicine, Marquette University School of Medicine, and the Department of Medicine, Milwaukee County Hospital.†This work was carried out at Milwaukee County Hospital under a grant from the Eli Lilly Drug Company.‡Supplied as Darvon by J. M. Maas, M.D., Lilly Research Laboratories.Requests for reprints should be addressed to R. W. Boyle, M.D., Milwaukee County Hospital, Milwaukee 13, Wisconsin. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDextropropoxyphene 1 January 1960Volume 52, Issue 1Page: 195-200KeywordsAnalgesicsClinical trialsDrugsElderlyGeriatricsHospital medicineOpiatesRehabilitation medicineResearch laboratories ePublished: 1 December 2008 Issue Published: 1 January 1960 PDF downloadLoading ...
Quantification of target gene expression by imaging reporter gene expression in living animals
Authors: Yajing Yu, Alexander J. Annala, Jorge R. Barrio, Tatsushi Toyokuni, Nagichettiar Satyamurthy, Mohammad Namavari, Simon R. Cherry, Michael E. Phelps, Harvey R. Herschman, Sanjiv S. Gambhir
Journal: Nature Medicine (2000)
Abstract 2318: The Type 2 Diabetes Gene <i>CDKAL1</i> Discovered by Genome-wide Association is Expressed in Beta Cells and Modulated by Glucose Concentration
Authors: Valgerdur Steinthorsdottir, Inga Reynisdottir, Gudmar Thorleifsson, Shyamali Ghosh, Rafn Benediktsson, Gunnar Sigurdsson, Augustine Kong, Mark Gurney, Jeffrey R Gulcher, Unnur Thorsteinsdottir, Kari Stefansson
Journal: Circulation (2007)

In our genome wide association study on type 2 diabetes (T2D), a variant we had previously identified in TCF7L2 stood out as the most significant finding. In addition, a variant of the CDKAL1 gene was found to be associated with increased risk of T2D in a nearly recessive manner, with genotype odds ratio for the homozygous carrier 1.45 and 1.55 for individuals of European and Asian ancestry respectively. The function of the CDKAL1 gene product is unknown but it is similar to another protein, CDK5RAP1, an inhibitor of the CDK5/p35 complex in neuronal tissue. This complex is also expressed in pancreatic beta cells and, in the presence of its active form, insulin expression is decreased under glucotoxic conditions. This led to the suggestion that CDKAL1 may be an inhibitor of the CDK5/p35 complex in beta cells, similar to the role of CDK5RAP1 in neuronal tissue. Furthermore, we have shown that the risk variant of CDKAL1 is associated with reduced insulin secretion and this effect is mostly seen for the homozygote where a 24% reduction in insulin response is observed compared to the heterozygous carriers or non-carriers. This is in line with the nearly recessive mode of inheritance observed for this variant with respect to disease risk. The aim of this study was to gain further insight into the functional role of CDKAL1 using the rat pancreatic beta cell line INS-1. The rat pancreatic beta cell line INS-1 was cultured in the presence of variable glucose concentration, ranging from 2.5–30 mM, to evaluate whether CDKAL1 expression is regulated by glucose concentration. We demonstrated that the expression of CDKAL1 in rat INS-1 cells varied according to glucose concentration in the culture medium with reduced expression detected under glucotoxic conditions compared to normal glucose concentration. This indicates that CDKAL1 expression in pancreatic beta cells is sensitive to glucose concentration. It is possible that this response to glucose may be affected in individuals carrying the variant of CDKAL1 that is associated to T2D. This could explain the reduced insulin secretion observed for these individuals in response to an oral glucose tolerance test.
Long-pulsed Nd:YAG laser vs. intense pulsed light for hair removal in dark skin: a randomized controlled trial
Authors: S.A. Ismail
Journal: British Journal of Dermatology (2011)

Journal Article Long‐pulsed Nd:YAG laser vs. intense pulsed light for hair removal in dark skin: a randomized controlled trial Get access S.A. Ismail S.A. Ismail Department of Dermatology, Al‐Jedaani Hospital, Jeddah, Saudi Arabia Sahar A. Ismail. E‐mail: Saharsotohy@yahoo.comPresent address: Assiut University, Faculty of Medicine, Dermatology Department, Assuit, 71515, Egypt. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 166, Issue 2, 1 February 2012, Pages 317–321, https://doi.org/10.1111/j.1365-2133.2011.10695.x Published: 01 February 2012 Article history Accepted: 06 October 2011 Published: 01 February 2012
Abstract 18646: Safety Aspects of High Intensity Interval Training versus Moderate Intensity Continuous Exercise Training in Patients Post Acute Coronary Syndrome
Authors: Douglas Hayami, Mathieu Gayda, Martin Juneau, Eric Thorin, Jean-François Larouche, Gabriel Lapierre, Jean-Claude Tardif, Anil Nigam
Journal: Circulation (2014)

Introduction: Exercise training in patients who have suffered an acute coronary syndrome is associated with a significant reduction in mortality and cardiovascular events. Moderate intensity continuous exercise training (MICET) is currently recommended. Recently, high-intensity interval training (HIIT), that utilizes short bursts of very intense efforts interspersed with periods of recovery, has been explored as an alternative to MICET. The safety aspects of HIIT in patients post acute coronary syndrome (ACS) have been poorly described. Methods: Thirty-seven low-risk patients post ACS (65% STEMI, fully revascularized, EF &gt; 40%, age 61±9 years, 8 women) were randomized 4 weeks to 6 months post ACS; to 12 to 18 weeks of 2-3 sessions/week (total: 36 sessions) of isocaloric MICET or HIIT on cycle ergometer. VO2peak and maximal aerobic power (MAP) were determined using maximal cardiopulmonary exercise test (CPET) on cycle ergometer and continuous ECG and BP were monitored every 2 min. Cardiometabolic profile (body composition, blood lipids, BP), arrhythmias (24h-holter monitoring) and left ventricular ejection fraction (LVEF) were measured before and after the intervention. MICET consisted of: 5 min of warm-up period, 37 min at 60% maximal aerobic power (MAP) and 5 min of cool down. HIIT included: 5 min of warm-up, 3 sets of 10 minutes of repeated phases of 15 sec at 100% MAP alternating with 15 sec passive recovery and 5 min of cool down. Results: Significant improvement in VO2peak (normalized by lean body mass (LBM)) was observed in the MICET group only (MICET VO2peak: 29.26±4.87 vs. 34.26 mL/min/LBM, p&lt;0.05), but not in the HIIT group (HIIT VO2peak: 30.01±6.36 vs. 30.81±4.88 mL/min/LBM, p&gt;0.05). No significant improvements in body composition, BP or blood parameters were observed in either group. No adverse events including no increase of ventricular arrhythmias or deterioration of LVEF were noted with HIIT (56±6 vs. 57±7%, p&gt;0.05). Conclusion: In patients post-ACS, MICET appeared to have a greater impact on VO2peak compared to HIIT, while no improvement in cardiometabolic risk profile was observed in either group. HIIT was well tolerated and was not associated with increased ventricular arrhythmias or deterioration of cardiac function.
PROGNOSIS IN SOME PSYCHOSOMATIC DISEASES
Authors: H W BROSIN
Journal: Annals of Internal Medicine (1952)

Article1 October 1952PROGNOSIS IN SOME PSYCHOSOMATIC DISEASESHENRY W. BROSIN, M.D., F.A.C.P.HENRY W. BROSIN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-37-4-745 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPhysicians are constantly searching for means to improve their ability to "foretell the cause and termination of a disease" and also "the outlook afforded by this" knowledge. The skills and concepts of John Hunter, W. W. Gull, James MacKenzie and William Osler are being broadened and deepened by the new facts which are crowding upon us from our daily practice. This is especially true for those "successes" which leave something to be desired. A few examples will illustrate how we are compelled to enlarge our working concepts of physiology and of a patient as an organism dependent upon his social...Bibliography1. BormanSchmallenberg MCHC: Suicide following cortisone treatment, J. A. M. A. 146: 337-338 (May 26) 1951. CrossrefMedlineGoogle Scholar2. ClarkBauerCobb LDWS: Preliminary observations on mental disturbances occurring in patients under therapy with cortisone and ACTH, New England J. Med. 246: 205-216 (Feb. 7) 1952. CrossrefMedlineGoogle Scholar3. Menninger KA: Changing concepts of disease, Ann. Int. Med. 29: 318-325, 1948. LinkGoogle Scholar4. RomeBraceland HPFJ (a) : The psychological response to ACTH, cortisone, hydro-cortisone and related steroid substances, Am. J. Psychiat. 108: 641-651 (March) 1952. (b) Rome, H. P., and Braceland, F. J.: Psychological response to corticotropine, cortisone, and related steroid substances, J. A. M. A. 148: 27-30 (Jan. 5) 1952. CrossrefMedlineGoogle Scholar5. RossHayMcDowell WDTMF: The incidence of certain vegetative disturbances in relation to psychoses, Psychosom. Med. 12: 179-183, 1950. CrossrefMedlineGoogle Scholar6. SwartzSemrad JEV: Psychosomatic disorders in psychoses, Psychosom. Med. 13: 314-321, 1951. CrossrefMedlineGoogle Scholar7. Uniker TE: What comes after Dilantin? Psychoanalyt. Rev. 37: 363-364, 1950. MedlineGoogle Scholar8. KoskoffWeniger YDFL: The adverse effects upon a family resulting from a radical change of personality in one member after frontal lobotomy, Proc. A. Research Nerv. and Ment. Dis. 29: 148-154, 1949. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Pittsburgh, Pennsylvania*Presented at the Thirty-third Annual Session of the American College of Physicians, Cleveland, Ohio, April 24, 1952.From the Western Psychiatric Institute and Clinics, and the Department of Psychiatry, University of Pittsburgh School of Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPeptic ulcer and mental disorder—II 1 October 1952Volume 37, Issue 4Page: 745-750 Issue Published: 1 October 1952 PDF downloadLoading ...
Doxycycline for Stabilization of Abdominal Aortic Aneurysms
Authors: C. Arnoud Meijer, Theo Stijnen, Martin N.J.M. Wasser, Jaap F. Hamming, J. Hajo van Bockel, Jan H.N. Lindeman
Journal: Annals of Internal Medicine (2013)

Background: Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans. Objective: To test whether doxycycline inhibits AAA progression in humans. Design: Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345) Setting: 14 Dutch hospitals. Patients: 286 patients with small AAAs between October 2008 and June 2011. Intervention: Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months. Measurements: The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery. Results: Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups. Doxycycline treatment was associated with increased aneurysm growth (4.1 mm in the doxycycline group vs. 3.3 mm in the placebo group at 18 months; difference, 0.8 mm [95% CI, 0.1 to 1.4 mm]; P = 0.016 mm). Twenty-one patients receiving doxycycline and 22 patients receiving placebo had elective surgical repair (Kaplan–Meier estimates were 16.1% for those receiving doxycycline and 16.5% for those receiving placebo; difference, −0.4% [CI, −9.3% to 8.5%]; P = 0.83). Time to repair was similar in the groups (P = 0.92). Limitations: This study focuses on patients with small AAAs. As such, whether the data can be extrapolated to larger AAAs (>55 mm) is unclear. The high number of elective repairs (n = 43) was unanticipated. Moreover, the study did not follow patients who withdrew because of an adverse effect. Conclusion: This trial found that 18 months of doxycycline therapy did not reduce aneurysm growth and did not influence the need for AAA repair or time to repair. Primary Funding Source: The Netherlands Organisation for Health Research and Development, and the NutsOhra Fund.